New: Utrecht Centre of Excellence for Affordable Biotherapeutics
The Utrecht University and the World Health Organization (WHO) will work together to provide affordable patent free medicines in developing countries. Both organisations signed an agreement on March 2 in which the University makes its relevant knowledge available for the production of such medicines in The Utrecht Centre of Excellence for Affordable Biotherapeutics for Public Health (“UCAB”).
UCAB’s mission is to improve global health by helping to make high quality and affordable biotherapeutics accessible to patients throughout the world in a sustainable fashion.The first project, respiratory syncytial virus (RSV) is the leading cause of hospitalisations in infants and young children and the leading cause of acute lower respiratory infections (ALRI) in children globally. The annual global incidence of RSV infection has been estimated at 64 million and is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, of which 96% occur in developing countries.Source: University of Utrecht